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Abstract: Preterm birth continues to provide an enormous challenge in the delivery of perinatal 
health care, and is associated with considerable short and long-term health consequences 
for surviving infants. Progesterone has a role in maintaining pregnancy, by suppression of 
the calcium–calmodulin–myosin light chain kinase system. Additionally, progesterone has 
recognized anti-inflammatory properties, raising a possible link between inflammatory processes, 
alterations in progesterone receptor expression and the onset of preterm labor. Systematic reviews 
of randomized controlled trials evaluating the use of intramuscular and vaginal progesterone in 
women considered to be at increased risk of preterm birth have been published, with primary 
outcomes of perinatal death, preterm birth 34 weeks, and neurodevelopmental handicap in 
childhood. Eleven randomized controlled trials were included in the systematic review, involving 
2714 women and 3452 infants, with results presented according to the reason women were 
considered to be at increased risk of preterm birth. While there is a potential beneficial effect 
in the use of progesterone for some women considered to be at increased risk of preterm birth, 
primarily in the reduction in the risk of preterm birth before 34 weeks gestation, it remains 
unclear if the observed prolongation of pregnancy translates into improved health outcomes 
for the infant.
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The extent of preterm birth
Preterm birth, is defined by the World Health Organisation as birth prior to 37 completed 
weeks of gestation,1 and continues to provide an enormous challenge in the delivery 
of perinatal health care, estimated to affect approximately 13 million births annually 
worldwide.2 The incidence of preterm birth is variably reported between 5% and 
11% of all births,3,4 and its prevention continues to remain elusive, with many reports 
indicating an increase in the prevalence of preterm birth over recent years.5–7 Many 
factors have been implicated, including an increase in maternal age and use of assisted 
reproductive techniques, with resultant increases in the risk of multiple pregnancy,8–10 
increasing maternal body mass index and the influence of obesity,11 continued maternal 
smoking during pregnancy,12,13 and infection. However, recent reports from Denmark6 
and Australia7 demonstrate an increase in the occurrence of spontaneous preterm birth 
among women considered to be at low risk of 22% and 12% respectively.
Health consequences of preterm birth
Infants born preterm are over 40 times more likely to die during the neonatal period than 
are term infants,14,15 and while the risk is greatest for infants born at earlier gestational International Journal of Women’s Health 2009:1 74
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ages, this increased risk of mortality persists even for infants 
born between 32 and 36 weeks gestation.16 While preterm 
birth contributes a relatively small proportion of total births, 
it is associated with in excess of 70% of the total perinatal 
mortality in developed countries, when excluding deaths 
related to congenital anomalies.8,12,17
For surviving infants, there are significant health 
implications, particularly in relation to immature lung 
development, with respiratory distress syndrome being a 
major consequence of preterm birth,18 and the most significant 
cause of early neonatal mortality and morbidity.16 Infants 
often require respiratory support, with a significant proportion 
requiring mechanical ventilation. Up to 20% of surviving 
infants remain dependent on oxygen therapy 28 days after 
birth, with 25% diagnosed with chronic lung disease.19 
Other well-documented health complications include 
intraventricular hemorrhage and periventricular leukomalacia, 
with implications for ongoing cerebral dysfunction,20 
infectious morbidity,21 and specific neonatal conditions associ-
ated with prematurity, including retinopathy of prematurity22 
and necrotising enterocolitis.23 Infants continue to be at 
increased risk of hospitalization in the first year of life.24,25 
In the longer-term, children have ongoing risks of motor and 
sensory impairment,26,27 and subsequent handicap, including 
cerebral palsy.28 Additionally, infants born preterm have 
well recognized learning difficulties,29–33 behavioral prob-
lems,32,34–36 and continue to be at an educational disadvantage 
that persists into adulthood.37,38
Economic costs of preterm birth
The immediate and longer-term monetary costs related to 
preterm birth and neonatal intensive care unit admissions 
are considerable. Figures from the United States in 1990, 
estimated a weekly cost of approximately $US10,000 per 
preterm baby, increasing considerably with earlier gestational 
age at birth.39 More recent US figures suggest the annual 
cost of preterm birth has escalated to in excess of US$26 
billion,5 with the costs being greatest for infants born at 
earlier gestational ages.40
These figures relate primarily to intensive care unit costs, 
without consideration of costs related to ongoing care. Using 
data from Oxfordshire and West Berkshire, United Kingdom, 
Petrou and colleagues have compared the cumulative use and 
cost of hospitalisation to age 5 years, according to gestational 
age at birth.25 The duration of hospital admissions for infants 
born prior to 28 weeks gestation was 85 times greater when 
compared with infants born at term, with an adjusted mean 
cost difference of $US 22,789 per infant over the first 5 years 
of life.25 Infants born between 28 and 31 weeks gestation had 
16 times longer duration of hospitalisation, with an adjusted 
mean cost difference of $US18,654 per infant over the first 
5 years of life.25
Clements and colleagues have conducted population-
based estimates of the costs related to infant and toddler 
development services utilised by preterm infants in the first 
three years of life.41 Total programme costs approached $US 
66 million, with the mean cost per infant $US857.41 Costs 
varied considerably with gestational age at birth, increasing 
from $US725 per infant born at term, to $US1,578 per infant 
born between 32 and 36 weeks gestation, to $US5,393 per 
infant born between 24 and 31 weeks gestation.41
These economic estimates relate primarily to intensive 
care unit costs, without consideration of costs related to 
ongoing care, or of the enormous emotional and personal 
costs for families and individuals who are born preterm.
Recurrence of preterm birth
The “cause” of preterm birth is multifactorial, with social, 
psychological, and biological factors playing a role.42–45 
The most significant and consistently identified risk factor 
for preterm birth is a woman’s history of previous preterm 
birth.46–54 Estimates suggest the rate of recurrent preterm 
birth in this group of women is 22.5%,55 a 2.5 times 
increased relative risk when compared with women with 
no previous spontaneous preterm birth.56 For women with 
a history of a single preterm birth, the recurrence risk in a 
subsequent pregnancy is approximately 15%, increasing to 
32% where there have been two previous preterm births.57 
Approximately 30% of women who give birth between 
20 and 31 weeks gestation will birth prior to 37 weeks in a 
subsequent pregnancy,47 and for approximately 10% of these 
women, the preterm birth will occur at a similar gestational 
age.47,54,58 In up to 50% of cases of preterm birth, the cause 
is spontaneous onset of labor or preterm premature rupture 
of membranes (PPROM).17,59–61
The role of progesterone  
in preterm labor
The exact mechanism of the onset of both term and 
preterm labor in humans is a complex interaction of many 
different hormonal pathways, culminating in co-ordinated 
uterine contractile activity, mediated by the production 
of prostaglandins.62–64 Before birth, coordinated uterine 
activity is associated with connective tissue changes result-
ing in cervical ripening and dilatation.64 Progesterone has an 
essential role in maintaining pregnancy,65–67 primarily through International Journal of Women’s Health 2009:1 75
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establishing uterine quiescence.68,69 This is achieved through 
suppression of the calcium-calmodulin-myosin light chain 
kinase system, reducing calcium flux and altering the resting 
potential of smooth muscle.64,66
There is considerable debate about the relationship 
between progesterone withdrawal70 and the onset of labor.71 
In humans, the progesterone receptor (PR) has two major 
subtypes PR-A and PR-B. Binding of progesterone to PR-A, 
the short form of the receptor, not thought to be associated 
with intra-cellular pathway mechanisms, prevents the actions 
of progesterone mediated by PR-B.71 An increase in the 
myometrial PR-A to PR-B expression ratio occurs at the onset 
of labor at term, resulting in an increase in myometrial PR-A, 
and in effect a functional withdrawal of progesterone,71,72 
with increasing sensitivity to contractile stimuli.65,67,73,74 
Prostaglandins produced prior to the onset of labor, also act 
to increase the PR-A/PR-B expression ratio, and therefore the 
potential to initiate a functional withdrawal of progesterone.67 
In many animals the onset of labor is associated with a 
decrease in progesterone concentrations,62,64,65,75 but this has 
not been shown to occur in women before term or preterm 
birth, with no apparently detectable changes to circulating 
steroid hormone levels evident.64,65,67,76,77
Progesterone as an anti- 
inflammatory agent
In both term and preterm labor, there is evidence of an 
increase in inflammatory markers tumor necrosis factor 
(TNF) -alpha, interleukin-1 (IL-1) and interleukin-6 (IL-6), 
and down-regulation of the anti-inflammatory interleukin-10 
(IL-10).78,79 Inflammatory cytokines may alter enzyme expres-
sion, increasing prostaglandin production prior to the onset 
of labor.78,79 These maternal inflammatory mediators may 
then interact at the feto-placental unit, precipitating preterm 
birth.80 In particular, inflammatory cytokines interleukin-1 
and TNF-alpha act to increase prostaglandin production, 
while both IL-10 and progesterone have a negative effect 
on prostaglandin production.63
It is in this context that progesterone may exert its anti-
inflammatory properties, raising a possible link between 
inflammatory process, alterations in progesterone receptor 
expression and the onset of preterm labor.81 While it has 
been postulated that the effect of progesterone on preterm 
birth is related to its anti-inflammatory properties, the 
specific mechanism of action remains unclear. A number 
of investigators have developed models of inflammation in 
pregnant animals and examined the effect of pre-treatment 
with progesterone on inflammatory mediators.
Elovitz and colleagues have developed a mouse model 
of intra-uterine inflammation with intrauterine injection 
of lipopolysaccharide (LPS).82–84 In these experiments, 
pre-treatment with progesterone was associated with 
suppression of activation of contraction-associated genes 
and inflammatory mediators, as well as prevention of the 
cervical ripening response to intrauterine inflammation.82 
Pre-treatment with progesterone was associated with a 
reduction in preterm labor and preserved fetal viability in 
the mouse.82,83 In a subsequent experiment, the influence 
of progesterone on Toll-like receptors was evaluated.84 
Toll-like receptors are involved in both the initiation and 
modulation of the inflammatory response, and regulation 
of these receptors may be one mechanism whereby 
intrauterine inflammation mediates the onset of labor, and 
therefore modifiable by the administration of progesterone.84 
Pre-treatment of mice with progesterone prior to the creation 
of an intra-uterine inflammatory environment, was associated 
with a decrease in the LPS induced up-regulation of receptors 
in both the cervix and placenta.84 The authors concluded that 
this may be a potential mechanism whereby progesterone 
acts to reduce the risk of preterm birth.82–84
Other investigators85,86 have evaluated the anti-
inflammatory effect of progesterone at the feto-placental 
unit. Placental chorionic plate arteries were exposed to 
either lipopolysaccharide alone or in combination with 
progesterone. Exposure to LPS alone was associated with 
an increase in the production of the inflammatory cytokine 
IL-6.85,86 Pre-treatment of the arteries with progesterone 
was associated with reduced production of IL-6 after LPS 
exposure, although there was no demonstrable effect on 
the concentrations of TNF-alpha or IL-10.85,86 Similarly, 
exposure to progesterone was associated with a reduction in 
both fetal and maternal mononuclear cell expression of IL-6 
after exposure to LPS, again suggesting these cell populations 
as possible targets for the anti-inflammatory effects of proges-
terone, and a potential mechanism for the observed reduction 
in preterm birth following progesterone.85,86
Pharmacokinetics of progesterone 
by route of administration
Current information about the pharmacokinetics of pro-
gesterone relates to its use in assisted reproduction,87–90 in 
menopausal91 and post-menopausal women,88 92 and in women 
with endometrial carcinoma.93 These studies indicate blood 
progesterone concentrations following vaginal administra-
tion to be lower than after intramuscular administration.89,90 
There are few data available to inform the optimal route of International Journal of Women’s Health 2009:1 76
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administration in women in later pregnancy. For 100 mg 
vaginal progesterone pessaries the peak blood concentrations 
are obtained 3 to 8 hours after vaginal administration, due 
to avoidance of first pass hepatic metabolism. In blood, 
progesterone is 96% to 99% protein bound, mainly to 
albumin. While there may be advantages in the use of 
intramuscular progesterone in terms of increased blood 
concentrations, such preparations are not available in many 
countries world-wide.
Safety of progesterone
Natural progesterone has been used in pregnancy without 
demonstrated effect on fetal development or on the risk of 
congenital anomalies.94,95 Information from animal studies 
suggests that progesterone influences fetal behavior in 
sheep,96 with increased concentrations suppressing activity 
and arousal states.97,98 Much of the information relating to 
childhood outcomes dates to more than 30 years ago, utilising 
a variety of progestogenic agents.99–102 Recognized maternal 
side-effects related to progesterone therapy include headache, 
nausea, breast tenderness, and coughing.
Is there clinical evidence to suggest 
a role for progesterone in preventing 
preterm birth?
The administration of progesterone as a therapeutic agent for 
the prevention of preterm birth dates to the early 1960s,103 
with considerable renewed interest in its use following 
recent reports of randomized controlled trials published first 
in 2003.104,105
There have been several systematic reviews of randomized 
controlled trials evaluating the use of both intramuscular and 
vaginal progesterone in women considered to be at increased 
risk of preterm birth published,106–111 in addition to many 
narrative reviews.112–115
In considering the effects of progesterone for preterm 
birth, the most recent systematic reviews will be considered 
in more detail.108,109 The prespecified primary outcomes 
were perinatal death, preterm birth 34 weeks, and 
neurodevelopmental handicap in childhood.108,109 Eleven 
randomized controlled trials were included in the systematic 
review, involving 2714 women and 3452 infants, with results 
presented according to the reason women were considered 
to be at increased risk of preterm birth.108,109 Characteristics 
of these studies are presented in Table 1.
For women with a past history of spontaneous preterm 
birth, progesterone was associated with no significant dif-
ference in perinatal death (3 studies, 1114 participants, 
relative risk [RR] 0.65, 95% confidence interval [CI] 0.38 
to 1.11); but a reduction in preterm birth prior to 34 weeks 
(1 study; 142 women; RR 0.15; 95% CI 0.04 to 0.64; number 
needed to treat (NNT) 7; 95% CI 4 to 17) (Table 2).108,109 
While there was a significant reduction in the risk of infant 
birth-weight less than 2500 g (2 studies, 501 infants, RR 
0.64, 95% CI 0.49 to 0.83), there were no other differences 
identified between the two treatment groups for secondary 
neonatal outcomes. It is important to bear in mind that the 
combined sample size of 1329 infants is underpowered to 
reliably detect differences of clinical relevance in markers of 
neonatal morbidity and mortality. The report by Northen116 
details the 2 year follow-up of 278 participants from the 
Meis randomized trial.105 While only 60% of infants were 
available for follow-up, this study did not identify statistically 
significant differences between the progesterone and placebo 
treatment groups in the risk of childhood developmental delay 
(RR 0.97; 95% CI 0.55 to 1.73).108,109
Information about the optimal route of progesterone 
administration is insufficient. Of particular note, the largest 
study to date using vaginal progesterone gel identified no 
benefit for women with a previous preterm birth.117 However, 
the results of ongoing randomized trials assessing the role 
of intramuscular118 and vaginal119,120 progesterone in women 
with a history of spontaneous preterm birth will contribute 
information about the role of progesterone in this group of 
women (Table 3).
For women considered to be at increased risk of 
preterm birth due to the identification of a short cervix on 
ultrasound, progesterone was associated with no significant 
difference in perinatal death (1 study, 274 participants, RR 
0.38, 95% CI 0.10 to 1.40); but a significant reduction in 
preterm birth before 34 weeks (1 study; 250 women; RR 
0.58; 95% CI 0.38 to 0.87; NNT 7; 95% CI 4 to 25).108,109 
While the study reported a significant reduction in the risk 
of neonatal sepsis,121 the sample size of 250 is underpowered 
to reliably detect differences in neonatal outcomes. There 
is a single registered randomized trial evaluating the use of 
intramuscular122 progesterone in nulliparous women with a 
short cervix identified on transvaginal ultrasound and this will 
contribute important information when completed.
The role of progesterone to prevent preterm birth in 
women with a multiple pregnancy is far less certain. Two 
randomized trials were included evaluating the use of 
progesterone in women with a multiple pregnancy.123,124 The 
primary outcome for the Rouse study124 was a composite 
of birth before 35 weeks gestation or death, with no 
statistically significant differences identified between the International Journal of Women’s Health 2009:1 77
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progesterone and placebo groups. The only pre-specified 
primary outcome was perinatal death, with no significant 
differences identified (1 study, 154 participants, RR 1.95, 
95% CI 0.37 to 10.33). While the use of progesterone 
was associated with a reduction in the use of antenatal 
tocolysis,124 there were no differences identified for other 
secondary infant and maternal health outcomes. The role 
of intramuscular125–127 and vaginal128–131 progesterone in 
women with a multiple pregnancy is the subject of several 
ongoing randomized studies.
Two studies were included in the systematic review 
where women presenting following treatment for threatened 
preterm labor received progesterone therapy for the remainder 
of their pregnancy,132,133 but none of the pre-specified 
primary outcomes were reported.108,109 Neither study 
utilized a placebo, and outcome assessors were not blinded, 
increasing the potential for bias. An ongoing trial assessing 
the role of vaginal progesterone134 in women presenting with 
symptoms or signs of threatened preterm labor will contribute 
information in the future.
For women with “other” risk factors that were considered 
to increase the risk of preterm birth, progesterone was 
not associated with a significant difference in perinatal 
death (2 studies, 264 participants, RR 1.10, 95% CI 0.23, 
5.29).108,109 No other statistically significant differences were 
identified for the outcomes reported.
While there is information available from randomized 
trials suggesting that progesterone therapy may be beneficial 
for some women considered to be at increased risk of pre-
term birth, for some pregnancy outcomes, there is more 
limited information available relating to neonatal and infant 
health outcomes. In particular, there is little information 
about the benefits and harms of progesterone in relation to 
long-term infant outcomes. Information is available from the 
follow-up of a single randomized trial related to long-term 
infant and childhood health outcomes.116 While this report 
indicates no statistically significant differences in health and 
developmental assessment at 2 years of age, only 60% of 
participants were available for assessment.116 Therefore, the 
longer-term follow-up of participants in randomized trials 
remains a priority.
Maternal outcomes after antenatal progesterone therapy 
have to date been poorly reported, including treatment 
side-effects, preferences of mode of administration and 
satisfaction with their pregnancy care. Further information 
is required on these important issues.135,136
Similarly, there is insufficient information available 
to date to be able to make valid recommendations about 
the optimal dose, route of administration, and gestational 
age at which to commence progesterone therapy, with 
utilisation of both vaginal and intramuscular preparations. 
There is considerable variation in the dose of progesterone 
administered, ranging from 90 mg daily117 to 400 mg 
daily132 when administered vaginally, and from 250 µg 
weekly,105,123,124,137 to 250 µg every 3 days,138 341 µg every 
4 days,133 up to 1000 µg weekly.139 The optimal time to 
commence therapy also varies considerably across studies, as 
does the duration of treatment. While the majority of studies 
commenced therapy in the mid-late second trimester at 24 to 
28 weeks gestation,104,117,121,123,132,133,138 others commenced 
in the first trimester at the time of antenatal “booking”,137 
and still others from 16 weeks gestation.105,124,139 Similarly, 
there may be differences in the mechanism of action of 
natural progesterone (administered vaginally), compared 
Table 2 Summary findings reported in systematic reviews105,106 for primary outcomes by reason at risk of preterm birth
Reason at risk of 
preterm birth
Outcome Number of   
studies
Number of  
participants
Relative   
risk
95% confidence 
interval
Previous preterm birth Perinatal death
Preterm birth less 
than 34 weeks
Childhood 
developmental delay
3
1
 
1
1114
142
 
275
0.65
0.15
 
0.97
0.38 to 1.11
0.04 to 0.64
 
0.55 to 1.73
Ultrasound identified 
short cervix
Perinatal death
Preterm birth less 
than 34 weeks
1
1
274
250
0.38
0.58
0.10 to 1.40
0.38 to 0.87
Multiple pregnancy Perinatal death 1 154 1.95 0.37 to 10.33
Following symptoms 
or signs of threatened 
preterm labor
Nil primary 
outcomes reported
“Other” reason Perinatal death 2 264 1.10 0.23 to 5.29International Journal of Women’s Health 2009:1 80
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with the 17-hydroxyprogesterone caproate which has been 
most commonly administered to date as an intramuscular 
preparation.
Conclusion
Preterm birth remains a significant problem in obstetric 
care, affecting women and babies world-wide. There are 
considerable health consequences for infants born preterm, 
as well as economic consequences for the health care system, 
individuals, and their families. Improving health outcomes 
for preterm infants requires improvements in care for infants 
who are born preterm, or developing effective strategies that 
can reduce the chance of an infant being born preterm.
While the precise mechanism of both term and 
preterm labor remains unclear, progesterone plays an 
important role in the maintenance of pregnancy through the 
maintenance of uterine quiescence. Increasingly, there is 
information suggesting that progesterone may potentially 
mediate a woman’s risk of preterm birth acting as an anti-
inflammatory agent.
Interest in the use of progesterone as a therapeutic agent 
to reduce the risk of preterm birth dates back to the 1960s. 
Recent randomized trial reports have re-ignited the interest in 
progesterone for this indication. Evidence from randomized 
controlled trials and systematic reviews indicates a potential 
beneficial effect in the use of progesterone for some women 
considered to be at increased risk of preterm birth, primarily 
in the reduction in the risk of preterm birth before 34 weeks 
gestation. However, it remains unclear if the observed 
prolongation of pregnancy translates into improved health 
outcomes for the infant, as to date there is more limited 
information available about neonatal and longer-term 
infant health. Ongoing randomized trials, and in particular 
follow-up of participants into childhood, will contribute 
valuable information, and over time, help to establish the 
precise role of progesterone for women considered to be at 
increased risk of preterm birth.
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